Jeffrey P. Steinhoff

Jeffrey P. Steinhoff

Auto-generated profile, based on publicly available information

Jeffrey P. Steinhoff

HCA Florida Largo Hospital

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
ARAbdullah Rathur
Abdullah Rathur
HAHussein Al-Mohamad
Hussein Al-Mohamad
JSJeffrey Steinhoff
Jeffrey Steinhoff
RWRonald Walsh
Ronald Walsh
Introduction. Gastropericardial fistula, a connection between the upper gastrointestinal tract and pericardium, is a rare clinical finding most commonly associated with postsurgical complications, as well as direct tissue invasion from gastric cancer. Case Report. We report a case of a 58-year-old Caucasian woman with metastatic colon cancer treated with FOLFOX, a combination chemotherapy regimen, and bevacizumab who presented with chest pain. She was ruled out for acute coronary syndrome, aortic dissection, or pulmonary embolism. A computed tomography (CT) scan of her chest showed pneumopericardium. A barium swallow ruled out esophageal ulceration, and esophagogastroduodenoscopy (EGD) showed a large penetrating gastric ulcer with no evidence of gastric dysplasia or malignancy or evidence of Helicobacter pylori (H. pylori). The patient underwent median sternotomy with gastric ulcer resection and repair, as well as pericardial washout and pericardial chest tube placement. After an uncomplicated course, she was safely discharged home. Conclusion. Given that gastrointestinal ulceration and perforation are known phenomena in patients taking vascular endothelial growth factor (VEGF) inhibitors, surveillance endoscopy may be beneficial to discover them before they result in potentially fatal complications such as gastropericardial fistulas.

14 December 2000 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Closed access
GWG. Weitz
G. Weitz
HDH. Djonlagic
H. Djonlagic
PMP. Montzka
P. Montzka
JSJ. Steinhoff
J. Steinhoff
CDChristoph Dodt
Christoph Dodt
Anamnese und klinischer Befund: Eine 18-jährige Schülerin mit Kopf- und Gliederschmerzen, Fieber, Erbrechen, Diarrhö und orthostatischer Synkope wurde wegen eines akuten Nierenversagens aus einer auswärtigen Klinik zu uns verlegt. Die Patientin war somnolent, der Blutdruck betrug 90/60 mmHg, die Herzfrequenz 104/min, die Körpertemperatur 39,1˚C. Am Körperstamm fiel ein sonnenbandähnliches Exanthem auf. Untersuchungen: In den Laboruntersuchungen fanden sich niedrige Werte für Thrombozyten und Kalzium, sowie erhöhte Werte für Leukozyten, C-reaktives Protein, Kreatinin, Bilirubin, Transaminasen, Kreatinkinase und Laktat. Das Röntgenbild zeigte diffuse Verschattungen, die Patientin war hypoxisch. Im rechten Unterbauch ließ sich durch bildgebende Diagnostik eine walnussgroße Raumforderung abgrenzen. Die mikrobiologischen Befunde waren außer einer vaginalen Besiedlung mit »toxic-shock-syndrome-toxin-1«-(TSST-1-)bildendem Staphylococcus aureus unauffällig, der Serum-Antikörpertiter gegen TSST-1 war kleiner 1:25. Diagnose, Therapie und Verlauf: Auf Grund einer Assoziation mit Menstruation und Tamponbenutzung vermuteten wir ein toxisches Schocksyndrom (TSS) mit Multiorganbeteiligung. Ein noch liegender Tampon wurde entfernt. Die iliakale Raumforderung erwies sich laparoskopisch als Hämatom. Da eine bakterielle Sepsis nicht auszuschließen war, behandelten wir mit einer breiten Antibiose, die übrige Therapie war symptomatisch. Die Patientin erholte sich innerhalb von acht Tagen vollständig. Die charakteristische Hautschuppung bestätigte die Diagnose des Toxischen Schocksyndroms (TSS). Folgerungen: Die Diagnose des TSS ist in der Akutphase mit Unsicherheiten behaftet. Die Initialsymptome sind unspezifisch und erlauben zahlreiche Differentialdiagnosen. Eine Bestätigung der Diagnose ist - wenn überhaupt - erst in der Rekonvaleszenzphase anhand der Hautschuppung oder eines Anti-TSST-1-Antikörper-Titeranstiegs möglich. Zur Abgrenzung eines nicht-menstruellen TSS ist auch bei Assoziation mit der Menstruation eine Fokussuche erforderlich. History and admission findings: An 18-year-old schoolgirl was reffered for admission by another hospital because of headache, joint pains, fever, vomiting, diarrhoea and orthostatic syncope associated with renal failure. On admission he was somnolent with a blood pressure of 90/60 mmHg, heart rate of 104 beats/min and a slight fever of 39,1˚C. A sunburn-like skin rash was noted. Investigations: Laboratory tests indicated low levels of platelets and calcium, increased levels of white cells, C-reactive protein, creatinine, bilirubin, transaminases, creatinekinase and lactate. Chest X-ray demonstrated diffuse shadows, while other imaging revealed a space-occupying lesion, ca. 3 cm in diameter, in the right lowere quadrant of the abdomen. The patient was hypoxic. Microbiology revealed vaginal colonies of Staph. aureus (producing toxic shock syndrome toxin 1 [TSST-1]). Serum antibody titre against TSST-1 was less than 1:25. Diagnosis, treatment and course: A toxic shock syndrome (TSS) with multi-organ involvement was suspected because of the association of menstruation with the use of tampons. An inserted tampon was removed. At laparoscopy the space-occupying lesion proved to be a haematoma. As bacterial septicaemia could not ne excluded broad-spectrum antibiotics were administered together with symptomatic measures. The patient fully recovered within a week. The characteristic skin desquamation confirmed the diagnosis of TSS. Conclusion: In its acute phase the diagnosis of TSS is often uncertain. The initial symptoms are nonspecific and numerous conditions need to be considered in the differential diagnosis. The diagnosis can be confirmed, if at all, only in the convalescent phase by the skin desquamation or a rise in anti-TSST-1 antibody titre. A search for a focus of infection is essential for differentiation from a non-menstrual TSS, even if there is as association with menstruation.

28 March 2024 in Annals of Thoracic Surgery Short Reports
Verified
Journal Article
Open access
JSJeffrey P. Steinhoff
Jeffrey P. Steinhoff
SKSahiti Kolli
Sahiti Kolli
MMMeredith P. Mattlin
Meredith P. Mattlin
DSDaniel Schlauch
Daniel Schlauch
ABAndrew T. Braisted
Andrew T. Braisted
GFGregory P. Fontana
Gregory P. Fontana
Current treatment guidelines for infective endocarditis focus on left-sided infective endocarditis. Because right-sided infective endocarditis has different presentations and outcomes, it is crucial to further delineate surgical outcomes for isolated tricuspid valve endocarditis (TVE). This retrospective study reviewed 374 surgically treated patients with isolated TVE from January 2012 through April 2022 who underwent isolated tricuspid valve surgical procedures. Primary outcomes were in-hospital mortality, permanent pacemaker need, and postsurgical inotropic support. The in-hospital mortality was 4% (n = 15). Patients with liver disease had 3.81-times higher odds of death vs no liver disease (odds ratio [OR], 3.81; 95% CI, 1.22-12.17). A pacemaker was required in 17% of patients without a prior pacemaker, which was 4.07 times the odds with tricuspid valve replacement (OR, 4.07; 95% CI, 1.72-11.60) vs tricuspid valve repair. Each yearly increase in patient age demonstrated lower odds of permanent pacemaker requirement by 7% (OR, 0.93; 95% CI, 0.89-0.97). The odds for postoperative inotropic support increased 2.55-times higher in patients receiving preoperative inotropic agents (OR, 2.55; 95% CI, 1.29-5.05), 2.27-times higher with renal failure (OR, 2.27; 95% CI, 1.38-3.74), and 86% higher in patients administered preoperative heparin (OR, 1.86; 95% CI, 1.14-3.02). Mortality of surgical treatment for TVE was 4%, with higher risks with liver disease. Tricuspid valve replacement was associated with higher odds for permanent pacemaker vs repair. Renal failure, preoperative inotropic support, and preoperative heparin were associated with higher odds for postoperative inotropic support. These findings further illustrate surgical outcomes with TVE.

12 November 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
ASAbhinav Singh
Abhinav Singh
JSJeffrey P. Steinhoff
Jeffrey P. Steinhoff
ALAnton Lishmanov
Anton Lishmanov
VSVivek Singh
Vivek Singh
STShaival Thakore
Shaival Thakore
SSSaurabh Sanon
Saurabh Sanon
Background: Optimal antithrombotic therapy after left atrial appendage occlusion remains uncertain. Methods: We studied 2817 patients undergoing left atrial appendage occlusion at 8 hospitals from 2016 to 2023 using registry data linked to Medicare claims. Among 2448 Watchman FLX recipients, the primary exposure was time‐varying dual antiplatelet therapy (DAPT) versus pooled direct oral anticoagulant (DOAC)‐based therapy. Outcomes were major adverse cardiovascular events (MACE), major bleeding, and device complications. The primary instrumental‐variable analysis used operator FLX preference; overlap weighting was secondary and pairwise regimen comparisons exploratory. Results: DAPT was associated with lower MACE (absolute risk difference [ARD], −1.5% [95% CI, −1.9% to −1.0%]; number needed to treat, 67) and major bleeding (ARD −1.6% [95% CI, −2.0% to −0.9%]; number needed to treat, 63) than pooled DOAC‐based therapy, without increased device complications. Overlap‐weighted associations with MACE and major bleeding were nonsignificant. In exploratory pairwise analyses, DAPT did not differ significantly from DOAC monotherapy for MACE or major bleeding; lower major bleeding was limited to DAPT versus DOAC plus single antiplatelet therapy (ARD, −0.6% [95% CI, −1.1% to −0.2%]; P =0.008). Most estimated benefit accrued within 6 months. Conclusions: DAPT was associated with lower MACE and major bleeding than pooled DOAC‐based therapy after Watchman FLX implantation. The safety benefit was concentrated in the comparison with DOAC + single antiplatelet therapy, whereas DAPT and DOAC monotherapy did not clearly differ in either outcome. These findings support randomized trials comparing DAPT with DOAC monotherapy.